Bharat Biotech and GSK announce price reduction for the world's first malaria vaccine to under $5. This move aims to improve access and save thousands of children in malaria-endemic countries.

By Maggie Fick and Jennifer Rigby LONDON (Reuters) -Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to below $5 per dose by 2028, more than halving its current cost, they ...

As part of a multi-year collaboration, GSK and India’s Bharat Biotech are redoubling their efforts to bring the world’s first malaria vaccine to more countries in need at affordable prices.

GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the ...

India Business News: HYDERABAD: Vaccine maker Bharat Biotech International Ltd and British biopharma giant GSK plc will be slashing the prices of the world’s first malaria.

Hyderabad-based Bharat Biotech has partnered with GSK—a British multinational pharmaceutical and biotechnology company—for the ongoing development and potential use of the Shigella vaccine ...

Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners, by ...

In a recent development, Bharat Biotech and GSK announced a price reduction of $5, which aims to improve access and save thousands of children who suffer from malaria.

Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to below $5 per dose by 2028, more than halving its current cost, they said on Wednesday.